EvidenceHealthVitaminsSupplementsVitamin D
Monthly high-dose vitamin D in older adults: more falls with higher doses
- Study type:
- Randomised, double-blind clinical trial comparing different monthly high-dose vitamin D3 regimens in community-dwelling older adults at increased fall risk.
- Topic:
- Vitamin D dosing and fall prevention
- Added:
- 2026-05-01
- Status:
- published
Strength of evidence
Moderate
Source
Bischoff-Ferrari HA et al. Monthly high-dose vitamin D treatment for the prevention of functional decline in older adults: a randomized clinical trial. JAMA Intern Med. 2016;176(2):175–183.
Open original studyCommunity-dwelling older adults with increased risk of falling were randomised to **monthly vitamin D3 doses** roughly equivalent to: - 24,000 IU/month (about 800 IU/day), - 60,000 IU/month (about 2,000 IU/day), or - in some arms, 24,000 IU plus calcifediol. The higher-dose groups did **not** show better functional outcomes, and in fact experienced **more falls** than the moderate‑dose 24,000‑IU group. This well-conducted RCT provides **moderate-quality evidence** that pushing vitamin D to higher monthly bolus doses in older adults can **increase fall risk** instead of preventing it.
Key findings
- Older adults (≥70 years) living in the community with a history of falls and/or functional limitations were enrolled.
- Participants were randomised to different vitamin D3 regimens given **once per month** (e.g. 24,000 IU vs 60,000 IU, with or without additional calcifediol).
- Primary outcome: change in lower-extremity function (Short Physical Performance Battery, SPPB) over 12 months.
- Secondary outcome: **number of falls** during follow-up.
- No meaningful improvement in functional performance with higher doses.
- Participants receiving **higher monthly doses** (around 60,000 IU and/or with calcifediol) had a **higher incidence of falls** than those on the 24,000‑IU regimen.
- Increasing monthly vitamin D dose above a moderate level **did not help** and was associated with **more falls**.
Background
- Vitamin D is often promoted to older adults as a simple way to prevent falls and fractures. To improve adherence, some protocols use **intermittent high-dose regimens** (e.g. monthly or yearly) instead of daily pills. The assumption is that more vitamin D—or higher peaks—will better support muscle and bone.
- This trial tested whether **higher monthly doses** of vitamin D3 in older adults at increased fall risk improve physical function and reduce falls, compared with a more moderate monthly dose.
Methods
- **Population:** Community-dwelling older adults (mostly ≥70 years), with a history of falls or functional limitations, hence at **increased risk of falling**.
- **Design:** Randomised, double-blind clinical trial. Participants assigned to one of several **monthly vitamin D3 regimens**, including: 24,000 IU/month (≈800 IU/day equivalent) – moderate dose; 60,000 IU/month (≈2,000 IU/day equivalent) – higher dose; in some arms: 24,000 IU/month plus calcifediol (a more active vitamin D metabolite).
- **Duration:** Follow-up for about 12 months.
- **Endpoints:** **Primary:** change in lower-extremity function (Short Physical Performance Battery, SPPB). **Secondary:** incidence of **falls** during follow-up, plus other functional and safety measures.
Results
- **Functional performance (SPPB):** Higher vitamin D doses did **not** lead to superior improvements in SPPB compared with the 24,000‑IU group.
- **Falls:** Participants in the **higher-dose** arms (60,000 IU/month and/or with calcifediol) experienced **more falls** over the study period than those receiving 24,000 IU/month. The increased fall risk was dose-related: pushing vitamin D above a moderate monthly dose **did not protect** against falls and appeared to **worsen** outcomes.
- **Fractures:** The trial was not primarily powered for fracture outcomes, but there was **no clear fracture benefit** of the higher-dose regimens.
Interpretation
- This trial shows that in older adults with an elevated fall risk: Increasing vitamin D3 to **higher monthly bolus doses** (around 60,000 IU/month and/or adding calcifediol): **did not improve** lower extremity function compared with 24,000 IU/month, and was associated with **more falls**, not fewer.
- From a WorthDay perspective: This is a randomised, double-blind trial with hard, clinically relevant endpoints (falls), which justifies a **moderate evidence** rating for harm under the tested regimens apply specifically to **monthly high-dose regimens** in older adults at increased fall risk; they cannot be directly generalised to lower, daily doses or younger populations.
- Mechanisms for increased falls (e.g. transient effects on muscle or neuromuscular function) remain unclear.
- Follow-up was about one year; longer-term effects were not studied.
Limitations
- All participants received vitamin D; there was **no true placebo group without vitamin D**, so the trial compares different dosing regimens rather than "vitamin D versus no vitamin D".
- The results apply specifically to **monthly high-dose regimens** in older adults at increased fall risk; they cannot be directly generalised to lower, daily doses or younger populations.
- Mechanisms for increased falls (e.g. transient effects on muscle or neuromuscular function) remain unclear.
- Follow-up was about one year; longer-term effects were not studied.
WorthDay perspective
- S0055 adds another important warning to the vitamin D story: **More** is not automatically **better** – particularly when delivered as **high monthly bolus doses** in older adults.
- Under the WorthDay Evidence Criteria, the combination of S0053 (no benefit in healthy adults), S0054 (annual mega-bolus → more falls and fractures) and S0055 (monthly high dose → more falls) makes it very difficult to justify: population-wide high-dose vitamin D supplementation, or marketing vitamin D as a harmless, always-beneficial "sunshine pill."
- For WorthDay users: Vitamin D should be treated as a **potent hormone-like substance**, not a neutral vitamin candy. High-dose regimens in older adults deserve particular caution and strict medical justification, if at all.
Permalink: https://www.worth-day.com/science-compass/s0055-monthly-high-dose-vitamin-d-in-older-adults-more-falls-with
Related studies
- Calcium plus vitamin D in postmenopausal women: more kidney stones, limited fracture benefitS0056
- Annual high-dose vitamin D3 in older women: increased risk of falls and fracturesS0054
- Vitamin D3 supplementation in generally healthy adults: primary results of the VITAL trialS0053
- β‑Carotene Supplements & Lung Cancer in Male Smokers (ATBC)S0035
Science meets practice